Orbital cellulitis

Summary

Orbital cellulitis (MONDO:0006881) is a disease and 4 clinical trials. Top therapeutic interventions include dexamethasone, sulfamethoxazole, and trimethoprim. A subtype of acute orbital inflammation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	orbital cellulitis
Mondo ID	MONDO:0006881
EFO	EFO:1001076
MeSH	D054517
DOID	DOID:11234
ICD-11	1330743591
NCIT	C99000
SNOMED CT	194005002
UMLS	C0149507
MedGen	57681
MedDRA	10031036
Is cancer (heuristic)	no

Also known as: orbital cellulitis

Disease family

This is a subtype of acute orbital inflammation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › disease of orbital part of eye adnexa › acute orbital inflammation › orbital cellulitis

Related subtypes (3): orbital periostitis, orbital osteomyelitis, orbital tenonitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06982105	PHASE4	RECRUITING	Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
NCT07345819	Not specified	NOT_YET_RECRUITING	Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis
NCT01504568	Not specified	WITHDRAWN	The Use of Prophylactic Antibiotics in Isolated Blowout Fractures
NCT02711436	Not specified	UNKNOWN	Fast Magnetic Resonance Imaging as Compared to Computed Tomography Scan in Pediatric Orbital Cellulitis Imaging

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXAMETHASONE	4	1
SULFAMETHOXAZOLE	4	1
TRIMETHOPRIM	4	1